Welcome to our dedicated page for Karyopharm Therapeutics news (Ticker: KPTI), a resource for investors and traders seeking the latest updates and insights on Karyopharm Therapeutics stock.
Karyopharm Therapeutics Inc. reports developments tied to its commercial oncology business and selinexor-based drug development. The company markets XPOVIO (selinexor) and reports U.S. product revenue, license and other revenue, liquidity, and operating updates alongside its periodic financial results.
Recurring KPTI news also covers late-stage clinical programs evaluating selinexor in cancer indications, including the Phase 3 SENTRY trial in myelofibrosis and the Phase 3 XPORT-EC-042 trial in endometrial cancer. Company updates include clinical data presentations, regulatory-development disclosures, equity inducement grants under Nasdaq rules, financing activity, and other corporate and capital-structure matters.
Karyopharm Therapeutics (NASDAQ: KPTI) announced on February 1, 2023, the grant of 113,250 restricted stock units (RSUs) to ten newly hired employees as part of its 2022 Inducement Stock Incentive Plan. The RSUs will vest over three years, with one-third vesting each year, contingent upon the employees' continued service. These grants align with Nasdaq Listing Rule 5635(c)(4), offering incentives to attract talent. Karyopharm develops innovative cancer therapies, including XPOVIO® (selinexor), an oral exportin 1 inhibitor approved for multiple oncology indications in the U.S. and other regions.
Karyopharm Therapeutics announced preliminary unaudited revenue estimates for Q4 and full-year 2022. Total revenue is expected to be approximately $157.7 million, including U.S. XPOVIO net product revenue of $120.4 million, marking a 22% increase from 2021. The company initiated a pivotal Phase 3 study for selinexor in advanced endometrial cancer and plans further studies in myelofibrosis. Additionally, Karyopharm has extended its cash runway to late 2025, emphasizing strong revenue growth and promising clinical pipeline prospects for 2023.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a leader in cancer therapies, announced its participation in the 41st Annual J.P. Morgan Healthcare Conference. The presentation will occur on January 11, 2023, at 10:30 a.m. PT, followed by a Q&A session at 10:50 a.m. PT. A live webcast will be available on the Company's website and can be replayed for 30 days post-event. Karyopharm is known for its SINE compound technology and its lead product, XPOVIO®, which is approved for various oncology indications. For more details, visit www.karyopharm.com.
Karyopharm Therapeutics (Nasdaq: KPTI) reported promising results from the Phase 1 study of selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. At week 24, 92% of efficacy-evaluable patients achieved ≥35% spleen volume reduction (SVR35), while 67% showed ≥50% symptom reduction (TSS50). Additionally, 57% of transfusion-independent patients stabilized their hemoglobin levels. The company aims to advance this combination therapy into randomized trials, highlighting its potential to improve current treatment standards.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) announced a webcast on December 12, 2022, to present updated Phase 1 study results on selinexor combined with ruxolitinib for treating treatment-naïve myelofibrosis. Key opinion leaders, including Dr. Haris Ali and Dr. Srdan Verstovsek, will discuss data and the treatment landscape. The webcast will be accessible on the company's investor website. Karyopharm also has multiple presentations scheduled at the ASH 2022 Annual Meeting, focusing on its cancer therapies, particularly XPOVIO, which has various regulatory approvals worldwide.
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) has entered into a securities purchase agreement for a private placement expected to yield $165 million. The company will sell 31,791,908 shares of common stock at $5.19 per share, along with warrants for an additional 9,537,563 shares at an exercise price of $6.36. Proceeds will fund clinical development of selinexor and eltanexor, and general corporate purposes. The placement is set to close around December 7, 2022, pending standard conditions.
Karyopharm Therapeutics (Nasdaq: KPTI) announced the granting of stock options for 6,100 shares and 4,200 restricted stock units (RSUs) to two new employees as of November 30, 2022. The stock options have an exercise price of $5.29 per share, equivalent to Karyopharm's closing stock price on the grant date. Both stock options and RSUs will vest over four years, with specific conditions for early exercise tied to employment termination scenarios. These grants are in accordance with Nasdaq Listing Rule 5635(c)(4), aimed at facilitating recruitment.
Karyopharm Therapeutics (NASDAQ: KPTI), a leader in novel cancer therapies, announced its participation in two upcoming investor conferences in November 2022. The Jefferies 2022 London Healthcare Conference is scheduled for November 15, 2022, at 3:35 a.m. ET, featuring a fireside chat. The Piper Sandler 34th Annual Healthcare Conference will take place on November 29, 2022, at 11:30 a.m. ET, with a podium presentation. Webcasts of both events will be accessible for 90 days post-event on the company's investor webpage.
Karyopharm Therapeutics (KPTI) reported Q3 2022 total revenue of $36.1 million, with net product revenue from XPOVIO at $32.0 million, a 20% increase from Q3 2021. The company initiated a Phase 3 study for selinexor as maintenance therapy in advanced endometrial cancer. Encouraging data from a Phase 1 study of selinexor combined with ruxolitinib in myelofibrosis was highlighted, showing positive efficacy results. Karyopharm maintains its 2022 revenue guidance of $155 million to $165 million, emphasizing a cash runway into early 2024.
Karyopharm Therapeutics (Nasdaq: KPTI) announced promising results from a Phase 1 study on selinexor combined with ruxolitinib for treatment-naïve myelofibrosis. Preliminary efficacy showed 79% of patients achieved a ≥35% reduction in spleen volume at 12 weeks, with 86% at 24 weeks. The treatment also demonstrated significant symptom reduction in 69% of evaluable patients. Common adverse events were manageable, with no dose-limiting toxicities reported. Data on selinexor's effectiveness in triple-class refractory multiple myeloma will also be presented at the upcoming ASH Annual Meeting.